in December 2024 the FDA's Pharmacy Compounding Advisory Committee voted against adding it to the final 503A bulks list, citing nonclinical toxicity, an unresolved cardiac signal, and immunogenicity risk
Previous medications like Semaglutide (Wegovy/Ozempic) target only GLP-1, while Tirzepatide (Mounjaro/Zepbound) targets GLP-1 and GIP
In 1955, an Icelandic doctor suggested the name benign myalgic encephalomyelitis after noting some similarities in cerebrospinal fluid abnormalities between patients from the London Royal Free Hospital outbreak and other putatively similar outbreaks, including a 1948 outbreak in Akureyri, Iceland (Sigurdsson May 26, 1956, in The Lancet )
Both medications have shown effectiveness, but the right choice depends on your specific treatment goals, preferences for administration, and budget